In mouse models of schizophrenia (phencyclidine treated or NMDA receptor NR1 subunit knockdown mice), selective activation of β-arrestin 2 pathways with D2 dopamine receptor biased agonists reduced hyperlocomotion, restored pre-pulse inhibition, improved novel object recognition, improved social behaviors and reduced seizures (Park et al., 2016). The gene discussed is DRD2; the disease is schizophrenia.